CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 37 enrolled
Drug / intervention
PF-02545920 +3 moredrug
Likely dose
PF-02545920 15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01829048
NCT01829048Phase 1Completed
CompareCT.gov

A Randomized, Double-blind, Placebo Controlled, Sponsor Open, Phase 1b Study To Examine The Adjunctive Safety, Tolerability And Pharmacokinetics Of Pf-02545920 In Psychiatrically Stable Subjects With Schizophrenia

Pfizer·interventional·Posted Apr 11, 2013·Updated Aug 20, 2018

In Brief

A Phase 1 clinical trial evaluating PF-02545920 and Placebo for Schizophrenia. Completed, enrolled 37 participants across 1 site.

Detailed Summary

To evaluate the safety and tolerability of multiple doses of PF 02545920 administered orally to psychiatrically stable subjects with schizophrenia receiving background antipsychotic +/- other adjunctive medication.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 11, 2013
Enrollment StartMar 6, 2013
Primary CompletionOct 17, 2013
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 13.2 years ago

Interventions

PF-02545920drug

15 mg (2 mg X 2d, 5 mg X 2d, 8 mg X 3 d, then 15 mg) Q12h

PF-02545920drug

15 mg (5 mg X 2d, 10 mg X 2d, then 15 mg) Q12h

PF-02545920drug

15 mg (5 mg BID for 7 days 10 mg BID for 7 days, then 15 mg BID for 4 days) Q12h

Placebodrug

Placebo Q12h